English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/88094
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Recent strategies in the development of new human cytomegalovirus inhibitors

AuthorsMartínez, Ana ; Castro, Ana ; Gil, Carmen ; Pérez, Concepción
Issue Date2001
PublisherJohn Wiley & Sons
CitationMedicinal Research Reviews 21: 227- 244 (2001)
AbstractHuman cytomegalovirus (HCMV) is one of the most common opportunistic infections in immunucompromised individuals, such as AIDS patients and organ transplant recipients, and is the most frequent congenital viral infection in humans. Despite a reduction of the incidence of AIDS-related opportunistic infections in patients under highly active antiretroviral treatment, attention should be paid to the HCMV risk factor in these individuals. Furthermore, HCMV may have an important role in atherosclerosis. Existing antiviral treatments for the HCMV infection suffer from poor bioavailability, toxicity, and limited effectiveness, mainly due to the development of drug resistance. Fortunately there are novel and potentially very effective new compounds undergoing pre-clinical and clinical evaluation. This review provides an overview in the last five years of new HCMV inhibitors (chemical structures, SAR and new mechanisms of action) with the aim to provide new clues for the development of the future drugs against this opportunistic virus. © 2001 John Wiley & Sons, Inc.
URIhttp://hdl.handle.net/10261/88094
DOI10.1002/med.1008
Identifiersdoi: 10.1002/med.1008
issn: 0198-6325
e-issn: 1098-1128
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.